News and Announcements
Major Biopharmaceutical Signs to Up to MedAdvisor Patient Engagement Program
- Published July 01, 2016 4:35PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st July 2016, ASX Announcement
Highlights:
- MedAdvisor is collaborating with Bristol-Myers Squibb Australia (BMS) to deliver a patient engagement and education program concerning one of its products
- Commencing shortly the 12-month patient engagement program (PEP) is being delivered via MedAdvisor’s medication management platform
- This agreement will generate further PEP revenue for MedAdvisor
- Provides further strong validation for MedAdvisor’s platform from a leading global biopharmaceutical company
MedAdvisors Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it will be collaborating with the Australian subsidiary of leading global pharmaceutical company, Bristol-Myers Squibb Company, to deliver a new patient engagement and education program.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
